Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners

• Australian Prescriber, Suite 3/2 Phipps Close, Deakin, ACT 2600.

---

• 1. Juni P, Rutjes AW, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287-1288.
• 2. Kerr SJ, Mant A, Horn FE, et al. Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. Med J Aust 2003; 179: 403-407. <eMJA full text>
• 3. MacDonald T, Morant S, Goldstein J, et al. Chanelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003; 52: 1265-1270.
• 4. National Institute for Clinical Excellence. Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. London: NICE, 2001.
• 5. Rostom A, Dube C, Jolicoeur E, et al. Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2003.
• 6. Solomon DH, Glynn RJ, Bohn R, et al. The hidden cost of non-selective non-steroidal anti-inflammatory drugs in older patients. J Rheum 2003; 30: 792-798.
• 7. Kamath CC, Kremers M, Vanness DJ, et al. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value in Health 2003; 6: 144-157.